Dexpramipexole appears to slow symptom progression and reduce mortality in Phase 2 trial

Results of the first stage showed that receiving dexpramipexole appeared to slow the progression of symptoms measured both by the ALS Functional Rating Scale and by pulmonary capacity. The second stage had similar results, with slower disease progression and a reduced risk of death in participants receiving the higher dosage.

Categories: Research News  |  Tags: ALS, ALS community, amyotrophic lateral sclerosis, Biogen Idec, California Pacific Medical Center, Columbia University Medical Center, Craig Amburgey, Dan Moore, David Schoenfeld, dexpramipexole, Donald Archibald, Evan Ingersoll, Hiroshi Mitsumoto, James Mather, Jeremy Shefner, Juliet Moritz, Knopp Biosciences, Lou Gehrig's disease, Mary Sullivan, Massachusetts General Hospital, Massachusetts General Hospital (MGH) Neurology Clinical Trials Unit and ALS Center, Merit Cudkowicz MD, MGH Biostatistics, Michael Bozik, Mitochondrial dysfunction, neurodegenerative disease, Northeast ALS Consortium, Nuedexta, RASCALS Foundation, riluzole, Robert A. Stehlin Campaign for ALS, Robert Miller, State University of New York Upstate Medical University Syracuse, Valentin Gribkoff PhD  |  No comments